Trial Profile

A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jan 2026 Status changed from active, no longer recruiting to completed.
19 Sep 2024 Planned End Date changed from 31 Dec 2026 to 31 Dec 2025.
11 Sep 2024 Results investigating the effect of PD-1 blockade in patients with CLL, we performed scRNA-seq and paired scTCR-seq on enriched CD8+ T cells from longitudinal blood samples of 4 CLL patients during treatment with pembrolizumab and ibrutinib from this clinical trial presented at the CRI-ENCI: 8th Annual International Cancer, Immunotherapy Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com